Figure 5 | Scientific Reports

Figure 5

From: Identification of two early blood biomarkers ACHE and CLEC12A for improved risk stratification of critically ill COVID-19 patients

Figure 5The alternative text for this image may have been generated using AI.

RT-qPCR validation of biomarkers CLEC12A and ACHE. (a) Boxplot showing significantly decreased mean abundance of CLEC12A transcripts in the blood of non-survivors in comparison to survivors (two-sided Wilcoxon test with a total n = 33 (survivors n = 18 (day 0 n = 8, day 7 n = 10), non-survivors n = 15 (day 0 n = 9, day 7 n = 6)); unequal variance t-test (pCLEC12A = 0.017, pACHE = 0.007)). (b) Boxplot showing significantly increased mean abundance of ACHE transcripts in the blood of non-survivors in comparison to survivors (two-sided Wilcoxon test with a total n = 33 (see a); unequal variance t-test (pCLEC12A = 0.001, pACHE = 0.005)). The RT-qPCR values of CLEC12A and ACHE were normalized to the two housekeeping genes FPGS and PEX16 to calculate a normalized 2-ΔΔCT value. (c) ROC curves for predicting the outcome of COVID-19 patients at day 0 using ACHE, CLEC12A, and a generalized linear model (GLM) that combines both biomarkers. (d) ROC curves for predicting the outcome of COVID-19 patients at day 0 using a GLM based on CRP and PCT (GLMCRP,PCT = I), SOFA score (II), and a GLM of ACHE and CLEC12A (GLMACHE,CLEC12A = III).

Back to article page